Category: SeaPRwire

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

SUMMIT, N.J. – December 05, 2025 – (SeaPRwire) – Leapfrog Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units are expected to commence trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU. The Company, which is led by Matthew R. Pollard, Abhay N. Pande and Kevin M. Murphy, is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Each unit sold in the offering consists of one Class A ordinary share (an “ordinary share”) and one half of one redeemable warrant with a strike price of $11.50 per ordinary share exercisable within 5 years of the Company completing an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on the Global Market tier of The Nasdaq Stock Market LLC under the symbols “LFAC” and “LFACW,” respectively. BTIG, LLC is serving as the sole book-running manager of the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering was made only by means of a prospectus, copies of which, when available, may be obtained by contacting BTIG, LLC, 65 East 55 Street, New York, NY 10022, by emailing ProspectusDelivery@btig.com, or by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Leapfrog Acquisition Corp Leapfrog Acquisition Corp is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or engaging in any other similar business combination with one or more businesses or entities. The Company is led by Chief Executive Officer, Matthew R. Pollard, President and Chief Investment Officer, Abhay N. Pande and Chief Financial Officer, Kevin M. Murphy. The Company will prioritize businesses in the international energy supply chain and critical minerals sectors, including their related infrastructure in its search for attractive merger candidates. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Media Contact Company: Leapfrog Acquisition Corp Contact: Media Team Telephone: +1-201-379-4200 LinkedIn: https://www.linkedin.com/company/leapfrog-acquisition-corporation Email In the US: abhay@leapfrogspac.com Email In Asia: matt@leapfrogspac.com kevin@leapfrogspac.com

Hong Kong – December 01, 2025 – (SeaPRwire) – ORCA, a global leader in on-site food-waste digestion technology, has partnered with Polytek Engineering Co. Ltd. as its exclusive distributor and service partner for Hong Kong. This collaboration marks an important step in ORCA’s continued expansion in Hong Kong and contributes to its wider presence throughout the Greater Bay Area and Southeast Asia markets. Addressing Hong Kong’s Food Waste Challenge Hong Kong continues to face significant challenges in waste management. In 2023, the city disposed of an average of 10,884 tonnes of municipal solids waste (MSW) per day. Food waste remained the largest single component, accounting for 29% or about 3,191 tonnes daily (info.gov.hk). The government has made commendable progress—household food waste disposal fell by 12.6%, and recovery rates increased to 33% in 2023, up from 32% the previous year (info.gov.hk). Still, the commercial and industrial sector contributes close to 1,000 tonnes of food waste daily, underscoring the need for scalable, sustainable solutions that can complement existing initiatives and support Hong Kong’s long-term waste reduction goals (epd.gov.hk). A Partnership for Sustainable Impact ORCA Digesters provide on-site solutions that convert food waste into environmentally safe water, reducing transportation emissions, protecting landfill capacity, and helping businesses meet sustainability targets. Polytek Engineering is a trusted leader in professional kitchen, laundry, and cold storage systems, with decades of expertise in design, supply, installation, and after-sales service. Their role at the design and conception phase of projects uniquely positions them to integrate ORCA technology into new builds and retrofits, ensuring food waste diversion is considered from the outset. About ORCA ORCA is a pioneer in on-site food waste digestion technology, offering systems that help businesses reduce landfill and transportation reliance, cut greenhouse gas emissions and ultimately reduce food waste at the source. “This partnership marks an important step toward addressing Hong Kong’s pressing food-waste challenge,” said Louis Anagnostakos — CEO, ORCA. “While ORCA continues to operate as an independent global company, by integrating our innovative technology with Polytek’s engineering expertise we can accelerate adoption of sustainable solutions across the commercial sector and the wider Greater Bay Area.” About Polytek Engineering Co. Ltd Polytek Engineering Co. Ltd is a leading provider of professional kitchen, laundry, and cold storage solutions in Hong Kong, Macau, and Mainland China. With expertise across design, supply, installation, and long-term service, Polytek delivers high-performance solutions tailored to client needs. “Polytek has always focused on delivering high-performance, future-ready kitchen and facility solutions,” said Joseph Tsang — General Manager, Polytek. “Through this exclusive partnership, we can now bring ORCA’s proven food waste technology into projects at the earliest design stage—helping our clients build sustainability directly into their operations from inception.”

New York, NY – November 22, 2025 – (SeaPRwire) – Innovative Warehouse Solutions (IWS), a leading New York-based eCommerce fulfillment company, has officially signed a partnership deal with Amazon Shipping, Amazon’s small parcel delivery network. Historically focused solely on supporting Amazon’s own eCommerce operations, Amazon Shipping now reaches 90% of the U.S. population with transit speeds that compete with UPS Ground and USPS Ground Advantage. In 2024 alone, the service delivered 5.7 billion packages, securing its position as the largest small parcel carrier in the U.S. by volume. Addressing questions about the unusual nature of a fulfillment company partnering with its biggest competitor, Brian Gibbons, CEO of IWS, emphasized that Amazon is a net positive for the entire eCommerce ecosystem. Now in his early 40s, Gibbons recalled a time when online shopping felt risky, noting that Amazon transformed the industry by introducing safety, trust, and standards. This foundation enabled a generation of entrepreneurs to launch businesses—from Shopify stores to multi-channel operations—with Gibbons adding, “We’re all kind of standing on Amazon’s shoulders.” Gibbons confirmed that most brands supported by IWS also sell on Amazon, framing the platform as a core channel akin to Sears or Macy’s in the 1990s, but not the sole revenue stream. “Smart brands diversify,” he explained, noting that IWS clients typically sell across Shopify, Amazon, Faire, Bloomingdale’s, and other platforms. IWS’s strength lies in its omni-channel fulfillment solution, which aggregates orders from all channels, leverages a centralized inventory pool, and tailors fulfillment to each channel’s unique requirements—resulting in lower holding costs and greater efficiency for brands. When asked what IWS offers that Amazon cannot, Gibbons acknowledged Amazon’s exceptional operational efficiency but highlighted customization as a key differentiator. Services like retail EDI, kitting, and channel-specific packaging are areas where third-party fulfillment providers like IWS deliver more value, as Amazon likely does not see sufficient ROI to prioritize these tailored offerings. Gibbons cited multiple factors driving the partnership with Amazon Shipping, starting with the stagnation of the small parcel 3PL industry over the past 20 years. While USPS’s Ground Advantage represented progress, legacy carriers continue to impose outdated surcharges—including residential delivery fees and fuel surcharges—even as residential deliveries have become standard. Amazon Shipping is disrupting this model by eliminating residential surcharges and offering deep discounts on fuel charges unless prices spike significantly, a change that Gibbons described as “huge for eCommerce brands.” Beyond cost, performance was a critical consideration. Gibbons noted that smaller carriers may offer attractive rates but often lack reach and speed, whereas Amazon Shipping provides 7-day-a-week delivery, faster windows for long-distance shipments, and employs uniformed drivers in branded trucks instead of gig workers. Additionally, the service includes delivery photo confirmation— a feature rarely offered at scale by other carriers. The partnership aligns with IWS’s mission to operate as an extension of its clients’ businesses: while clients manage product, marketing, and conversion, IWS handles logistics. This requires staying ahead of industry trends and identifying opportunities to enhance cost-effectiveness, speed, and reliability—all areas where Amazon Shipping excels. “In many cases, we’re giving our brands faster delivery at a lower cost,” Gibbons said. “That’s a no-brainer.” With this new partnership, IWS continues its commitment to providing flexible, tech-forward fulfillment solutions that empower growing eCommerce brands to thrive in an increasingly competitive market. Media contact Brand: Innovative Warehouse Solutions Contact: Media team Email: Info@invwhs.com Website: https://invwhs.com

SHENZHEN, CHINA – October 30, 2025 – (SeaPRwire) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/

Sejak beberapa tahun kebelakangan ini, Malaysia, dengan lokasi strategik dan pelbagai perjanjian perdagangan bebas, terus menarik kemasukan modal global. Menjelang 2024, sektor pembuatan dijangka menarik pelaburan yang diluluskan berjumlah RM 120.5 bilion, yang diunjurkan mencipta hampir 88,000 peluang pekerjaan. Dengan pecutan ekonomi digital dan persaingan bakat global yang semakin sengit, perniagaan dan pencari kerja di Malaysia menghadapi peluang dan cabaran yang belum pernah terjadi sebelum ini. Terutamanya dalam sektor pembuatan, pembinaan, dan perkhidmatan, permintaan terhadap pekerja kolar biru melonjak. Walau bagaimanapun, kecekapan rendah dan ketidakpastian maklumat saluran pengambilan tradisional telah menjadi halangan utama yang mengekang peningkatan ekonomi negara. JOBPD: Dilahirkan untuk Menyelesaikan Masalah Teras Pengambilan Pekerja Kolar Biru JOBPD ialah platform pengambilan pekerja kolar biru yang memberi tumpuan khusus kepada pasaran Malaysia. Ia komited untuk menyediakan pengalaman pengambilan yang revolusioner dan cekap kepada pencari kerja dan syarikat kolar biru, melalui pendigitalan, kepintaran, dan perkhidmatan tempatan. Kami percaya bahawa setiap pekerja yang gigih layak mendapat padanan yang lebih baik, dan setiap syarikat harus dapat mencari bakat yang sesuai dengan lebih pantas. Pasaran Kolar Biru: Peluang Besar yang Memerlukan Pendigitalan Keputusan kami untuk menumpukan perhatian pada pasaran kolar biru adalah berdasarkan pemahaman mendalam tentang data ekonomi makro dan struktur pekerjaan Malaysia: Permintaan Tenaga Kerja yang Kukuh dan Sokongan Struktur Industri Industri Tonggak Ekonomi:Sektor perkhidmatan dan pembuatan Malaysia menyumbang 82.6% daripada KDNK negara secara keseluruhan, menjadikan sektor ini kawasan tarikan utama bagi tenaga kerja kolar biru. Peningkatan Struktur Gaji:Dengan kenaikan berterusan gaji minimum (RM 1,700/bulan) dan pertumbuhan gaji purata (purata RM 3,045/bulan pada 2024), tekanan kos buruh syarikat meningkat. Ini menjadikan permintaan untuk "pengambilan yang cekap" semakin mendesak. Dilema Kadar Pusing Ganti yang Tinggi:Jawatan kolar biru mempunyai kadar pusing ganti yang tinggi, kos pengambilan berulang syarikat adalah keterlaluan, dan saluran tradisional gagal menyokong rentak pengambilan yang pantas. Kecekapan Rendah dan Masalah Saluran Pengambilan Tradisional Pulau Maklumat:Maklumat pengambilan bertaburan dalam kalangan ejen, kumpulan Facebook, dan rangkaian WhatsApp, mengakibatkan kekurangan pengesahan dan ketelusan yang seragam. Halangan Komunikasi:"Tiada maklum balas selepas memohon" telah menjadi masalah umum bagi pencari kerja kolar biru, di mana kecekapan komunikasi dan penapisan syarikat adalah sangat rendah. Jurang Platform Mudah Alih:Walaupun lebih daripada 80% daripada pekerja kolar biru mengakses internet melalui telefon bimbit, mereka kekurangan platform pengambilan yang direka khusus untuk mereka yang mudah digunakan dan responsif serta-merta. Kesimpulan: Pasaran pengambilan pekerja kolar biru Malaysia amat memerlukan penyelesaian digital dan mudah alih yang dapat mengintegrasikan aliran data dan meningkatkan kecekapan komunikasi lebih daripada 10 kali ganda. Kelebihan Teras JOBPD: Membentuk Semula Pengambilan Kolar Biru dengan Teknologi JOBPD telah menterjemahkan pengalaman yang dikumpulkan oleh pasukan kami dalam bidang pengambilan, sumber manusia, produk internet, dan analisis data, menjadi kelebihan kompetitif yang unik dalam senario pengambilan pekerja kolar biru. Mentakrif Semula "Kecekapan dan Kepercayaan" dalam Pengambilan Algoritma Padanan Cerdas:Platform ini menggunakan algoritma AI untuk memadankan jawatan, lokasi, gaji, dan kemahiran secara komprehensif, mencapai padanan yang tepat dan mengurangkan kos saringan syarikat. Mekanisme Komunikasi Segera:Mengguna pakai model seperti "BOSS Zhipin" dan menggabungkannya dengan notifikasi komuniti tempatan dan media sosial, ia mencapai maklum balas ultra-pantas dan memendekkan kitaran pengambilan dengan ketara. Sokongan Pelbagai Bahasa:Antaramuka yang ringkas dan intuitif, menyokong pelbagai bahasa termasuk Bahasa Cina, Inggeris, dan Bahasa Melayu, memenuhi tabiat penggunaan dalam konteks pelbagai budaya. Membina Ekosistem Pembangunan Kerjaya yang Adil dan Telus Ketelusan Gaji dan Faedah:Syarikat mendedahkan maklumat gaji dan faedah secara terbuka, menghapuskan ketidakseimbangan maklumat dalam pengambilan dan meningkatkan kepercayaan pencari kerja. Sistem Perkhidmatan Pelbagai:Selain daripada platform pengambilan, JOBPD juga menyediakan perkhidmatan headhunter dan perkhidmatan penyumberan luar, memenuhi pelbagai keperluan tenaga kerja syarikat, daripada pekerja kolar biru hingga pekerja berkemahiran tinggi. Memperkasa Pertumbuhan Bakat:Lebih daripada sekadar "mencari kerja," JOBPD sedang membina sebuah ekosistem pertumbuhan kerjaya dan penggajian semula untuk pekerja kolar biru, membantu pencari kerja meningkatkan kemahiran dan mencapai pembangunan jangka panjang. Data Pertumbuhan Platform: Pecutan Pendigitalan Pengambilan Kolar Biru Sejak dilancarkan secara rasmi pada Oktober 2025, JOBPD telah berkembang dengan pantas, mempamerkan potensi pasaran yang kukuh melalui penempatan yang tepat dan pengalaman yang cemerlang: Kumulatif syarikat yang mendaftar melebihi 1,000, merangkumi industri yang padat dengan pekerja kolar biru seperti pembuatan, logistik, pembinaan, makanan & minuman, dan peruncitan; Pencari kerja yang berdaftar di platform melebihi 20,000 orang, dan terus meningkat pada purata kadar bulanan sebanyak 35%; Jawatan aktif harian melebihi 5,000; purata kitaran padanan jawatan dipendekkan kepada kurang daripada 48 jam; Kepuasan syarikat mencapai 92%, dengan hampir 70% syarikat memilih untuk terus menerbitkanjawatan; Kadar kejayaan penghantaran resume pencari kerja meningkat 3 kali ganda, mengurangkan kehilangan maklumat pengambilan dengan berkesan. Data ini menandakan bahawa JOBPD sedang menjadi salah satu platform yang paling pesat berkembang dalam pasaran pengambilan pekerja kolar biru Malaysia, dan sedang membentuk semula standard ekosistem pengambilan kolar biru melalui pendekatan teknologi. Visi dan Komitmen Kami Visi JOBPD adalah: Menjadi platform pengambilan yang paling dipercayai di Malaysia, memperkasa setiap pencari kerja untuk merealisasikan impian kerjaya mereka. Pasukan kami terdiri daripada pakar dalam bidang pengambilan, produk internet, dan analisis data, menggabungkan pengalaman industri yang mendalam dengan pemikiran inovatif. Kami berdedikasi untuk menjadikan JOBPD sebagai jenama penanda aras bagi transformasi digital dalam pengambilan pekerja kolar biru. Melalui platform Web, mudah alih, dan matriks komuniti/media sosial, JOBPD sedang memacu transformasi menyeluruh dalam kaedah pengambilan melalui teknologi: Untuk Pencari Kerja:Menyediakan peluang pekerjaan berkualiti tinggi dengan gaji yang lebih baik dan terjamin; Untuk Syarikat:Menyediakan perkhidmatan padanan bakat yang lebih tepat, cekap, dan kos rendah. JOBPD — Menjadikan Pengambilan Lebih Cekap, Membawa Impian Selangkah Lebih Dekat JOBPD sedang mengubah cara pengambilan pekerja di Malaysia. Memilih JOBPD adalah memilih kecekapan, ketelusan, dan masa depan.

Malaysia’s strategic location and web of free-trade agreements continue to draw global capital. In 2024 alone the manufacturing sector secured RM 120.5 billion in approved investments, projected to create almost 88,000 new jobs. As the digital economy accelerates and competition for talent intensifies, Malaysian employers and job-seekers face unprecedented opportunities—and bottlenecks. Manufacturing, construction and services are expanding rapidly, driving surging demand for blue-collar labor. Yet traditional hiring channels—fragmented, slow and opaque—have become a critical brake on the nation’s economic upgrade. JOBPD: Built to Solve Blue-Collar Hiring Pain-Points JOBPD is a Malaysia-focused blue-collar recruitment platform that uses digital, intelligent and hyper-local services to give workers and companies a revolutionary hiring experience. We believe every hard-working person deserves a better job match, and every employer should find the right talent—faster. A Massive, Undigitized Opportunity We zeroed-in on blue-collar for four hard reasons: Structural demand Services + manufacturing = 82.6 % of national GDP and the biggest absorbers of blue-collar labor. Minimum wage has risen to RM 1,700/month; 2024 average wages hit RM 3,045/month, pushing companies to hunt for “hiring efficiency”. High churn Blue-collar turnover is steep; repeat hiring costs are crushing; traditional channels can’t keep pace. Channel failure Jobs are scattered across brokers, Facebook groups and WhatsApp—no verification, no transparency. “Apply-and-ghost” is the norm; mobile usage among workers exceeds 80 %, yet no one has built a dead-simple, mobile-first platform for them. Conclusion: Malaysia needs a single, mobile solution that can consolidate scattered traffic and lift communication efficiency by 10×. JOBPD’s Edge: Technology That Re-invents Hiring We weaponize our team’s DNA in recruiting, HR, Internet products and data science to create defensible advantages: Efficiency & trust, re-defined AI matching engine weighs job, location, salary and skills for precision, slashing employer screening time. BOSS-Zhipin-style instant chat + local social-media push = sub-48-hour hiring cycles. UI in English, Chinese and Bahasa Melayu, built for Malaysia’s multicultural workforce. A fair, transparent career ecosystem Mandatory salary & benefits disclosure ends information asymmetry. Beyond job ads: head-hunting and labor-outsourcing cover everything from general workers to skilled trades. Up-skilling hub: training partnerships turn the platform into a career-growth and re-employment engine. Traction: Digitization at Speed Since going live in October 2025: 1,000+ companies onboard—manufacturing, logistics, construction, F&B, retail. 20,000+ registered job-seekers, growing 35 % month-on-month. 5,000+ active jobs daily; median time-to-hire < 48 h. 92 % employer satisfaction; ~70 % re-list their next vacancy. 3× jump in successful applications, cutting drop-off sharply. We are already one of Malaysia’s fastest-growing blue-collar platforms—and we’re just getting started. Vision & Promise To become Malaysia’s most trusted hiring gateway, empowering every worker to realise a career dream. Our cross-functional team—recruiting veterans, product geeks, data scientists—is committed to making JOBPD the benchmark brand for blue-collar digital transformation. Across web, mobile and social channels, we are rewiring how Malaysia hires: For workers: higher-paid, protected, quality jobs. For employers: precise, fast, low-cost talent matches. JOBPD—hire smarter, dream closer. We are changing the way Malaysia recruits. Choose JOBPD, choose efficiency, transparency and the future.

Montréal, Canada – October 16, 2025 – (SeaPRwire) – T-RIZE Group and École de technologie supérieure (ÉTS) are proud to announce that the Industrial Research Chair in Tokenization, established in 2024 under the leadership of Professor Kaiwen Zhang, has secured over CAD $3 million over five years in contributions and funding from major national funds such as Mitacs and the Natural Sciences and Engineering Research Council of Canada (NSERC) through the Mitacs Accelerate – NSERC Alliance Grants program. This highly competitive Canadian funding underscores the strength of a research program already underway since 2024 – one that has consistently delivered transformative results in blockchain sustainability, real-world asset tokenization, and decentralized federated learning. Building Canada’s Resilient Digital Future At the core of this Chair is a patent-pending communication protocol combined with decentralized federated learning frameworks. These innovations are designed to provide infrastructures that are: Resilient: able to withstand disruptions and adapt dynamically to changing conditions Efficient: optimized to reduce costs, latency, and energy consumption at scale Secure: enabling verifiable and trusted exchanges across distributed environments Sovereign: ensuring that Canada retains control over its critical digital systems and data flows Decentralized federated learning enhances tokenization systems by enabling privacy-preserving collaborative intelligence and real-time risk analysis across distributed networks, making infrastructures not only more secure and efficient but also more adaptive to institutional needs. Such capabilities are vital in an increasingly complex world, where robustness, trust, and independence are essential for both national competitiveness and global cooperation. “This recognition from Mitacs, NSERC, and ÉTS affirms our capacity to build sovereign and resilient infrastructures in an era defined by AI. Through Decentralized Machine Learning, T-RIZE ensures that intelligence remains secure, autonomous, and verifiable – the foundation of digital sovereignty in a world where AI power shapes nations.” – Madani Boukalba, CEO, T-RIZE Group Canada’s Vision in Action The over CAD $3 million in funding from Mitacs, a leading innovation organization, and NSERC Alliance is more than financial support – it is recognition that this research is shaping the future of sustainable and sovereign digital infrastructure. By backing proven, high-impact models, Canada is signaling its intent to lead in technologies that matter: efficient networks, scalable intelligent data architectures, and resilient systems aligned with international standards and sustainability goals. Academic and Industrial Leadership Under the guidance of Professor Kaiwen Zhang, one of Canada’s foremost experts in distributed systems, blockchain, and machine learning, the T-RIZE Chair brings together a team of PhD and postdoctoral researchers at ÉTS, working hand in hand with T-RIZE Group. Together, they are turning advanced research into deployable, institutional-grade systems that strengthen Canada’s position as a global leader in innovation. About Mitacs Mitacs places top-tier talent in Canadian firms to support industry-academia collaboration. This helps unlock innovation potential, de-risk R&D for firms, and build lasting academic-industry relationships. Through its national reach and international partnerships, Mitacs enables Canada to develop the next generation of a skilled and innovative workforce. About T-RIZE T-RIZE has the infrastructure to structure and tokenize a wide range of assets – such as real estate, digital bonds, and high-quality carbon credits – into digital structured products enhanced by federated learning for risk analytics. The platform operates across public and privacy-enabled networks, such as the Canton Network. It has the capacity to integrate insurance and digital ratings to make these products collateral-ready, with distribution conducted through regulated broker-dealers. T-RIZE has tokenized over US$100M, with US$1B in signed projects advancing within a US$5B+ pipeline. The RIZE utility token is the access point to its institutional ecosystem. For more information contact:Press Inquiries: press@T-RIZE.ioHead Office: 1155 René-Lévesque West, Suite 2500, Montreal, QC H3B 3X7, CanadaToronto Office: 130 King Street West, Suite 1900, Toronto, ON M5X 1E3, Canada